Don't miss real-time top news, insights, and interviews with the experts direct from the conference floor in Chicago. Sign up now to be reminded to tune in to OncLive News Network: On Location in Chicago.

Predicting Immunotherapy Response in Bladder Cancer

Thursday, March 21, 2019

When it comes to predicting response to checkpoint inhibitors for patients with urothelial carcinoma, PD-L1 status may not be the most accurate factor, explained Robert Dreicer, MD, deputy director of UVA Cancer Center, director of solid tumor oncology within the division of hematology/oncology and is a professor of medicine and urology at the University of Virginia. 

PD-L1 is not the most reliable predictor because there are many patients whose tumors are not PD-L1 positive who still respond to immunotherapy. More research in this field is still warranted. 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Videos
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.